GC: n

S: NIH – (last access: 5 November 2020); NHS – (last access: 5 November 2020).

N: 1. “gigantism due to activity of pituitary after normal growth has ceased,” 1886, from French acromégalie, from medical Latin acromegalia, from Greek akron “extremity, highest point, mountain peak, headland,” neuter of akros “at the furthest point” (from PIE root *ak- “be sharp, rise (out) to a point, pierce”) + megas “great” (fem. megale; from PIE root *meg- “great”). Said in contemporary literature to have been coined 1885 by French physician Dr. Pierre Marie.
2. Acromegaly, growth and metabolic disorder characterized by enlargement of the skeletal extremities. It is the result of overproduction of pituitary growth hormone (somatotropin) after maturity, caused by a tumour of the pituitary gland. Acromegaly is often associated with the abnormal growth in stature known as pituitary gigantism.
3. Acromegaly and gigantism are due to oversecretion of growth hormone. The most common cause is a GH secreting pituitary adenoma. Rarely, ectopic GH secretion or excess secretion of GHRH may be the cause.
4. Gigantism is characterized by tall stature and should be suspected in children three standard deviations above the mean. Acromegaly is characterized by large hands and feet, coarse facial features, broad nose, acne, hyperhidrosis, underbite, and teeth separation.

S: 1. OED – (last access: 5 November 2020). 2. EncBrit – (last access: 5 November 2020). 3&4. NCBI –,%2C%20underbite%2C%20and%20teeth%20separation (last access: 5 November 2020).

OV: acromegalia

S: GDT – (last access: 5 November 2020)

SYN: 1. Marie’s disease, Marie’s syndrome. 2. Pierre Marie’s disease.

S: 1. TERMIUM PLUS – (last access: 5 November 2020). 2. GDT – (last access: 5 November 2020).

CR: growth hormone